← Back to list
Point32Health medical drug program updates
Act
by Feb 1, 2026
Effective date
Feb 1, 2026
Identified
Jun 20, 2026
Summary
Point32Health (Harvard Pilgrim and Tufts) is adding prior authorization requirements for two new specialty drugs and resuming coverage of Elevidys gene therapy with updated criteria. All changes are effective February 1, 2026.
Get alerts when payers change rules like this one
We check Harvard Pilgrim Health Care and other payers every day and email you when a change matches your specialty and state.
Get Harvard Pilgrim Health Care alertsPolicy Monitoring is free. No card required.
What to do
by Feb 1, 2026 · 3 steps
01Billing team must update prior authorization requirements for J4302 (Ryoncil) for pediatric graft-vs-host disease, J3403 (Encelto) for macular telangiectasia, and J1413 (Elevidys) for Duchenne muscular dystrophy.
02Update billing system to flag these codes for prior auth verification.
03Review Point32Health Medical Necessity Guidelines for specific criteria before submitting claims.
Codes mentioned
J4302J3403J1413
Original notice
Point32Health medical drug program updates
point32health.org · Always check the source before changing claims.
Related changes
See all Harvard Pilgrim Health Care changes →Point32Health medical drug program updatesMediumEffective Oct 1, 2025 · Provider NewsletterPoint32Health medical drug program updatesMediumEffective Nov 1, 2026 · Prior AuthorizationPoint32Health medical drug program updatesHighEffective Oct 1, 2026 · Prior AuthorizationPoint32Health medical drug program updatesMediumEffective Aug 1, 2026 · Prior AuthorizationBrowse every Harvard Pilgrim Health Care change in the policy list